Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study
Nuria Carrillo(National Institutes of Health), William A. Gahl(National Institute of Child Health), Claire T. Driscoll(National Institutes of Health), Kennan Bradley(National Institutes of Health), Christina Slota(National Institutes of Health), Scott Berry(Queen's University), Bradley Class(National Institutes of Health), Rebecca Parks(National Institutes of Health Clinical Center), Joseph A. Shrader(National Institutes of Health Clinical Center), May Christine V. Malicdan(National Institutes of Health), John D. Heiss(National Institutes of Health), Colleen Jodarski(National Institutes of Health), Melanie Quintana(Berry & Associates (United States)), Marjan Huizing(National Human Genome Research Institute), Levent Bayman(University of Iowa), John Perreault(National Institutes of Health), Chia‐Ying Liu(DMS Imaging (France)), Christopher S. Coffey(University of Iowa), Carla Ciccone(National Institutes of Health), Petcharat Leoyklang(National Institutes of Health), Galen O. Joe(National Institutes of Health Clinical Center), Scott Van Wart(AngioDynamics (United States))
Cited by 55
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818